A Phase 2 interventional study of Phentolamine Ophthalmic Solution 0.75% and Pilocarpine in Presbyopia, sponsored by Opus Genetics, Inc. Completed at 17 sites in United States. Open to participants aged 40 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Opus Genetics, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing pilocarpine in Presbyopia — 2 open to participants now, 2 under way, 1 of them phase 3. Pilocarpine · Presbyopia.
Among the 10 studies testing pilocarpine in Presbyopia, this one is the 6th largest by enrollment, is one of 3 that started in 2021, is the only one in phase 2, and was the 4th registered.
336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.
Browse Presbyopia studies →2 of the 10 studies testing pilocarpine in Presbyopia are open now, in 1 country. Recruiting first, the newest first:
Southern College of Optometry · Sites in United States
Ages 45–64
CSPC Ouyi Pharmaceutical Co., Ltd.
Ages 40–65
By country, each count listing its studies:
Pilocarpine: first FDA approval 1974 (OCUSERT PILO-20). What it is approved for, and how studies give it, is on its page →
Of the 18 Presbyopia studies recruiting now, 7 (39%) set no upper age limit and 9 (50%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.
This study: 40 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2021.
This study's enrollment of 150 is above the median of 61 across 276 interventional studies indexed under Presbyopia.
Median enrollment 190 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 6 most frequent:
Opus Genetics, Inc is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Opus Genetics, Inc has 3 studies filed under Presbyopia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing pilocarpine in Presbyopia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of this study are:
To evaluate the efficacy of Nyxol + Pilocarpine to improve DCNVA in subjects with presbyopia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ophthalmic (in either eye):
Conjunctival hyperemia ≥ grade 2 on the CCLRU 4-point scale.
Systemic:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 drop of Nyxol (Treatment 1) and 1 drop of Pilocarpine (Treatment 2)
Drug: Phentolamine Ophthalmic Solution 0.75% · Drug: Pilocarpine
1 drop of Nyxol (Treatment 1)
Drug: Phentolamine Ophthalmic Solution 0.75%
1 drop of Pilocarpine (Treatment 2)
Drug: Pilocarpine · Other: Placebo
1 drop of Placebo (Treatment 1)
Other: Placebo
0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Also known as: Nyxol, Nyxol®
Pilocarpine ophthalmic solution
Topical sterile ophthalmic solution
Also known as: Phentolamine Ophthalmic Solution Vehicle
Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA
The primary efficacy endpoint was the percent of subjects with ≥ 15 letters of improvement in photopic binocular DCNVA on Visit 2 at 1 hour with POS + LDP compared to placebo alone. The improvement in binocular DCNVA for each subject was relative to the subject's own baseline value (Visit 1).
Time frame: Visit 2 at 1 hour
Percentage of Subjects With Improvement of ≥ 5, ≥ 10, and ≥ 15 Letters in DCNVA (Photopic) From Baseline
The percentage of subjects with improvement of ≥ 5, ≥ 10, and ≥ 15 letters in DCNVA (photopic) from Baseline at 0.5 hours, at 2 hours, at 3 hours, at 4 hours, and at 6 hours
Time frame: Visit 2 at 0.5 hours, at 2 hours, at 3 hours, at 4 hours, and at 6 hours
Percentage of Subjects With Improvement of ≥ 15 Letters in DCNVA (Photopic) at 1 Hour and With < 5 Letters of Loss in Photopic Binocular BCDVA From Baseline
The percentage of subjects with improvement of ≥ 15 letters in DCNVA (photopic) at 1 hour and with \< 5 letters of loss in photopic binocular BCDVA from Baseline
Time frame: Visit 2 at 1 hour
Percentage of Subjects With Improvement in DCIVA (Photopic) From Baseline
The percentage of subjects with improvement in DCIVA (photopic) from Baseline of ≥ 5, ≥ 10, and ≥ 15 letters
Time frame: Visit 2 at 1 hour, at 3 hours, and at 6 hours
| Milestone | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle |
|---|---|---|---|---|
| Started | 44 | 30 | 31 | 45 |
| Completed | 43 | 30 | 31 | 44 |
| Not completed | 1 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 |
The primary efficacy endpoint was the percent of subjects with ≥ 15 letters of improvement in photopic binocular DCNVA on Visit 2 at 1 hour with POS + LDP compared to placebo alone. The improvement in binocular DCNVA for each subject was relative to the subject's own baseline value (Visit 1).
| percentage of subjects with ≥ 15 letters | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle |
|---|---|---|---|---|
| Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA | 60.5 | 30.0 | 45.2 | 27.3 |
The percentage of subjects with improvement of ≥ 5, ≥ 10, and ≥ 15 letters in DCNVA (photopic) from Baseline at 0.5 hours, at 2 hours, at 3 hours, at 4 hours, and at 6 hours
| percentage of subjects with improvement | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle |
|---|---|---|---|---|
| % of subjects with improvement of ≥ 5 letters from baseline at 0.5 hours | 88.4 | 86.7 | 74.2 | 70.5 |
| % of subjects with improvement of ≥ 10 letters from baseline at 0.5 hours | 76.7 | 50.0 | 54.8 | 52.3 |
| % of subjects with improvement of ≥ 15 letters from baseline at 0.5 hours | 60.5 | 33.3 | 25.8 | 15.9 |
| % of subjects with improvement of ≥ 5 letters from baseline at 2 hours | 88.4 | 93.3 | 83.9 | 70.5 |
| % of subjects with improvement of ≥ 10 letters from baseline at 2 hours | 81.4 | 60.0 | 71.0 | 45.5 |
| % of subjects with improvement of ≥ 15 letters from baseline at 2 hours | 62.8 | 26.7 | 41.9 | 18.2 |
| % of subjects with improvement of ≥ 5 letters from baseline at 3 hours | 95.3 | 83.3 | 83.9 | 72.7 |
| % of subjects with improvement of ≥ 10 letters from baseline at 3 hours | 67.4 | 60.0 | 64.5 | 43.2 |
| % of subjects with improvement of ≥ 15 letters from baseline at 3 hours | 46.5 | 26.7 | 48.4 | 20.5 |
| % of subjects with improvement of ≥ 5 letters from baseline at 4 hours | 95.3 | 83.3 | 83.9 | 75.0 |
| % of subjects with improvement of ≥ 10 letters from baseline at 4 hours | 67.4 | 60.0 | 51.6 | 50.0 |
| % of subjects with improvement of ≥ 15 letters from baseline at 4 hours | 46.5 | 30.0 | 32.3 | 20.5 |
| % of subjects with improvement of ≥ 5 letters from baseline at 6 hours | 88.4 | 86.7 | 71.0 | 72.7 |
| % of subjects with improvement of ≥ 10 letters from baseline at 6 hours | 67.4 | 60.0 | 54.8 | 50.0 |
| % of subjects with improvement of ≥ 15 letters from baseline at 6 hours | 37.2 | 36.7 | 22.6 | 18.2 |
The percentage of subjects with improvement of ≥ 15 letters in DCNVA (photopic) at 1 hour and with \< 5 letters of loss in photopic binocular BCDVA from Baseline
| % of subjects with improvement | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle |
|---|---|---|---|---|
| Percentage of Subjects With Improvement of ≥ 15 Letters in DCNVA (Photopic) at 1 Hour and With < 5 Letters of Loss in Photopic Binocular BCDVA From Baseline | 60.5 | 30.0 | 41.9 | 27.93 |
The percentage of subjects with improvement in DCIVA (photopic) from Baseline of ≥ 5, ≥ 10, and ≥ 15 letters
| percentage with improvement | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle |
|---|---|---|---|---|
| % of subjects with improvement of ≥ 5 letters from baseline at 1 hour | 86.0 | 46.7 | 71.0 | 56.8 |
| % of subjects with improvement of ≥ 10 letters from baseline at 1 hour | 48.8 | 23.3 | 45.2 | 25.0 |
| % of subjects with improvement of ≥ 15 letters from baseline at 1 hour | 14.0 | 10.0 | 22.6 | 4.5 |
| % of subjects with improvement of ≥ 5 letters from baseline at 3 hours | 69.8 | 43.3 | 67.7 | 50.0 |
| % of subjects with improvement of ≥ 10 letters from baseline at 3 hours | 41.9 | 30.0 | 41.9 | 25.0 |
| % of subjects with improvement of ≥ 15 letters from baseline at 3 hours | 18.6 | 10.0 | 22.6 | 4.5 |
| % of subjects with improvement of ≥ 5 letters from baseline at 6 hours | 72.1 | 56.7 | 38.7 | 47.7 |
| % of subjects with improvement of ≥ 10 letters from baseline at 6 hours | 30.2 | 16.7 | 29.0 | 18.2 |
| % of subjects with improvement of ≥ 15 letters from baseline at 6 hours | 14.0 | 10.0 | 12.9 | 4.5 |
Collected over 9 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| POS 0.75% First, Then LDP 0.4% | 0/44 (0%) | 0/44 (0%) | 15/44 (34.1%) |
| POS 0.75% First, Then LDP Vehicle | 0/30 (0%) | 0/30 (0%) | 6/30 (20%) |
| POS Vehicle First, Then LDP 0.4% | 0/31 (0%) | 0/31 (0%) | 6/31 (19.4%) |
| POS Vehicle First, Then LDP Vehicle | 0/45 (0%) | 0/45 (0%) | 2/45 (4.4%) |
| Event | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle |
|---|---|---|---|---|
| Instillation site erythemaGeneral disorders | 6/44 | 3/30 | 2/31 | 0/45 |
| Installation site painGeneral disorders | 4/44 | 3/30 | 0/31 | 1/45 |
| Eye irritationEye disorders | 3/44 | 0/30 | 0/31 | 0/45 |
| Conjunctival hyperaemiaEye disorders | 2/44 | 2/30 | 0/31 | 0/45 |
| Visual acuity reducedEye disorders | 1/44 | 1/30 | 2/31 | 1/45 |
| Lacrimation increasedEye disorders | 2/44 | 0/30 | 0/31 | 0/45 |
| DysgeusiaGastrointestinal disorders | 1/44 | 1/30 | 0/31 | 0/45 |
| Eye painEye disorders | 1/44 | 0/30 | 1/31 | 0/45 |
| Eye pruritusEye disorders | 0/44 | 0/30 | 1/31 | 0/45 |
| Intraocular pressure increasedInvestigations | 0/44 | 0/30 | 1/31 | 0/45 |
| Age, Continuous(years) | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle | Total |
|---|---|---|---|---|---|
| Mean | 53.4 ± 5.63 | 52.8 ± 5.11 | 52.7 ± 5.21 | 53.2 ± 4.55 | 53.1 ± 5.09 |
| Sex: Female, Male(Participants) | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle | Total |
|---|---|---|---|---|---|
| Female | 38 | 23 | 18 | 29 | 108 |
| Male | 5 | 7 | 13 | 15 | 40 |
| Ethnicity (NIH/OMB)(Participants) | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 2 | 4 | 10 |
| Not Hispanic or Latino | 42 | 27 | 29 | 40 | 138 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 3 | 3 | 1 | 4 | 11 |
| White | 40 | 26 | 28 | 38 | 132 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Study eye, n (%)(Participants) | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle | Total |
|---|---|---|---|---|---|
| OD | 29 | 23 | 23 | 35 | 110 |
| OS | 14 | 7 | 8 | 9 | 38 |
| Iris color, n (%)(Participants) | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle | Total |
|---|---|---|---|---|---|
| Light blue | 5 | 6 | 3 | 6 | 20 |
| Dark blue | 0 | 2 | 2 | 3 | 7 |
| Blue with peripupillary brown | 14 | 5 | 7 | 9 | 35 |
| Uniform green | 1 | 1 | 3 | 4 | 9 |
| Green with brown iris ring | 5 | 4 | 4 | 4 | 17 |
| Central brown and peripheral green | 8 | 4 | 2 | 1 | 15 |
| Brown with some peripheral green | 3 | 2 | 5 | 4 | 14 |
| Brown | 7 | 6 | 5 | 13 | 31 |
| Irides type, n (%)(Participants) | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle | Total |
|---|---|---|---|---|---|
| Light | 25 | 18 | 19 | 26 | 88 |
| Dark | 18 | 12 | 12 | 18 | 60 |
| Baseline photopic BCDVA study eye, letters read(letters read at 4 m distance) | POS 0.75% First, Then LDP 0.4% | POS 0.75% First, Then LDP Vehicle | POS Vehicle First, Then LDP 0.4% | POS Vehicle First, Then LDP Vehicle | Total |
|---|---|---|---|---|---|
| Mean | 57.8 ± 3.46 | 57.9 ± 2.84 | 58.1 ± 3.00 | 59.2 ± 3.58 | 58.3 ± 3.31 |
20 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in May 2021, 3 months.
Results were first posted in Aug 2023, 2 years 2 months after primary completion.
Of 13 phase 2 interventional studies under Presbyopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 8. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Phentolamine · Pilocarpine
Opus Genetics, Inc